Defense Health Agency Contracting Activity - DHACA

Description

The FY14 DMRDP CRMRP Neuromusculoskeletal Injuries Research Award (NMSIRA) supports preclinical research and clinical trials on the functional utility of assistive devices related to the human-device interface, secondary health effects following severe extremity injury, and optimizing rehabilitation and device prescription for patients with severe extremity trauma.To meet the intent of the award mechanism, applications must specifically address one or more of the FY14 DMRDP CRMRP NMSIRA Focus Areas listed below. Applications proposing research outside of the Focus Areas listed below should not be submitted in response to this Program Announcement/Funding Opportunity.• Improving the functional utility of assistive devices related to the human-device interface (prostheses, orthoses, and other assistive devices)o Improvements in prosthetic socket comfort, residual limb health, and functiono Providing proprioceptive and other sensory inputs to the usero Improving user intent control of assistive devices• Improving the ability to predict, identify and reduce secondary health effects that develop after severe primary neuromusculoskeletal injuryo Determining factors that predict development and successful treatment of osteoarthritis, low back pain, or other musculoskeletal conditionso Intervention strategies to diminish falls and decrease fracture risko Strategies to improve treatment and rehabilitation of heterotopic ossification• Optimizing treatment strategies and sequence of progression throughout the rehabilitation process following severe extremity traumao Determining the optimal combination, dose, and timing of rehabilitative techniques to minimize impairments and maximize function and performanceo Objectively guiding prosthetic and/or orthotic prescription to minimize impairments and maximize function and performanceIf the proposed study involves the use of a drug or biologic that has not been approved by the Food and Drug Administration (FDA) for its investigational use, evidence that an Investigational New Drug (IND) exemption application has been submitted or will be submitted within 60 days of award is required. If the proposed study involves an Investigational Device that has not been approved or cleared by FDA for its investigational clinical use, the study may be required to comply with the FDA Investigational Device Exemption (IDE) regulations and evidence that an IDE has been submitted or will be submitted within 60 days of the award date or that the device is exempt from an IDE is required. The Government reserves the right to withdraw funding if the IND or IDE application has not been submitted to the FDA within 60 days of the DoD award date or if the documented status of the IND or IDE has not been obtained within 6 months of the award date.

Who can apply

• Unrestricted

Contact

CDMRP Help Desk <br/>301-682-5507
help@cdmrp.org